GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunniva Inc (XCNQ:SNN) » Definitions » COGS-to-Revenue

Sunniva (XCNQ:SNN) COGS-to-Revenue : 0.71 (As of Sep. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Sunniva COGS-to-Revenue?

Sunniva's Cost of Goods Sold for the three months ended in Sep. 2019 was C$3.79 Mil. Its Revenue for the three months ended in Sep. 2019 was C$5.36 Mil.

Sunniva's COGS to Revenue for the three months ended in Sep. 2019 was 0.71.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sunniva's Gross Margin % for the three months ended in Sep. 2019 was 29.34%.


Sunniva COGS-to-Revenue Historical Data

The historical data trend for Sunniva's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunniva COGS-to-Revenue Chart

Sunniva Annual Data
Trend Dec16 Dec17 Dec18
COGS-to-Revenue
0.32 0.58 0.58

Sunniva Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.49 0.63 0.85 0.71

Sunniva COGS-to-Revenue Calculation

Sunniva's COGS to Revenue for the fiscal year that ended in Dec. 2018 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=10.99 / 18.789
=0.58

Sunniva's COGS to Revenue for the quarter that ended in Sep. 2019 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3.788 / 5.361
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunniva  (XCNQ:SNN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sunniva's Gross Margin % for the three months ended in Sep. 2019 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 3.788 / 5.361
=29.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Sunniva COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sunniva's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunniva (XCNQ:SNN) Business Description

Traded in Other Exchanges
N/A
Address
200 Burrard Street, 1200 Waterfront Centre, P.O Box 48600, Vancouver, BC, CAN, V7X 1T2
Sunniva Inc is vertically integrated medical cannabis company committed to delivering safe, low-cost, high-quality products and services at scale. The company is focused on the cultivation, production and distribution of therapeutic solutions targeting two of the medical cannabis markets in the world: Canada and California.
Executives
Mark Hamish Kimmins Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)

Sunniva (XCNQ:SNN) Headlines

From GuruFocus

Smith & Nephew: A Medical Equipment Opportunity

By The City Letter 08-09-2022